SpectRx/Abbott Labs
This article was originally published in The Gray Sheet
Executive Summary
Sale of $2.8 mil. in SpectRx convertible redeemable preferred stock to Abbott is included in a joint pact to develop a continuous glucose monitor. An additional $2.5 mil. investment is anticipated Jan. 3. Expanding on an existing alliance between the firms, the revised agreement gives Abbott exclusive worldwide marketing rights to continuous monitoring as well as single-use monitoring applications of the SpectRx technology, which incorporates sensors worn on top of the skin to analyze glucose levels in interstitial fluid (1"The Gray Sheet" June 28, p. 19)
You may also be interested in...
SpectRx/Abbott Labs
Sale of an additional $2.5 mil. in convertible redeemable preferred stock to Abbott completes the purchase of a total of $5.3 mil. in convertible redeemable preferred stock as part of an agreement to jointly develop a continuous glucose monitor. An initial sale of $2.8 mil. in stock was announced late last year (1"The Gray Sheet" Dec. 20, p. 17)
SpectRx/Abbott Labs
Sale of an additional $2.5 mil. in convertible redeemable preferred stock to Abbott completes the purchase of a total of $5.3 mil. in convertible redeemable preferred stock as part of an agreement to jointly develop a continuous glucose monitor. An initial sale of $2.8 mil. in stock was announced late last year (1"The Gray Sheet" Dec. 20, p. 17)
SpectRx Expanding Clinical Study Of Continuous Glucose Monitoring System
SpectRx says it is looking to enroll investigators for the next round of clinical studies of the company's evolving continuous glucose monitoring system prototypes.